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Work in recent years has revealed an abundance of possible new treatment targets for fragile X
syndrome (FXS). The use of animal models, including the fragile X knockout mouse which
manifests a phenotype very similar to FXS in humans, has resulted in great strides in this direction
of research. The lack of Fragile X Mental Retardation Protein (FMRP) in FXS causes
dysregulation and usually overexpression of a number of its target genes, which can cause
imbalances of neurotransmission and deficits in synaptic plasticity. The use of metabotropic
glutamate receptor (mGluR) blockers and gamma amino-butyric acid (GABA) agonists have been
shown to be efficacious in reversing cellular and behavioral phenotypes, and restoring proper
brain connectivity in the mouse and fly models. Proposed new pharmacological treatments and
educational interventions are discussed in this chapter. In combination, these various targeted
treatments show promising preliminary results in mitigating or even reversing the neurobiological
abnormalities caused by loss of FMRP, with possible translational applications to other
neurodevelopmental disorders including autism.
17.1 Introduction
We are in an age of targeted treatments for neurodevelopmental disorders that began with
advances in neurobiology and the development of appropriate animal models for many
neurodevelopmental disorders. Although the focus of this book and this chapter is on fragile
X syndrome (FXS) and animal models for this disorder leading to targeted treatments, this is
a phenomenon that has occurred for many other neurodevelopmental disorders including
tuberous sclerosis (de Vries 2010), neurofibromatosis and other disorders of the RAS MEK
pathways (Rauen et al. 2010), Down syndrome (Rueda et al. 2008), Rett syndrome
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(Maezawa and Jin 2010), and others with a known gene deletion or mutation. Targeted
treatment strategies are only just beginning in autism, because it is a heterogeneous disorder
with no single gene mutation causing the majority of cases (Bent and Hendren 2010). Most
cases of autism involve abnormalities occurring in genes involved with synaptic plasticity,
brain connectivity, and/or gamma amino butyric acid (GABA) and glutamate imbalances so
that brain function is impaired (Belmonte and Bourgeron 2006; Kelleher and Bear 2008;
Pinto et al. 2010). Thus, the autism field is benefitting from advances in targeted treatment
for other disorders that are associated with autism, such as FXS, which is the most common
single gene disorder associated with autism (Hagerman et al. 2010). One reason that FXS is
a good model for autism is because FMRP is an RNA binding protein that transports,
stabilizes, and regulates the translation of hundreds of mRNAs at the synapse (Darnell et al.
2005; Zalfa et al. 2007; Bassell and Warren 2008; Darnell et al. 2011; Luo et al. 2010). Not
only does FMRP regulate many genes that when mutated lead to autism such as neuroligins,
neurorexins, and SHANK proteins (Darnell et al. 2011; Hagerman et al. 2010), but the levels
of FMRP in the brains of adult autistic patients have been documented to be low compared
to controls even in individuals that do not have a fragile X mutation (Fatemi and Folsom
2010). Not only autism but other neuropsychiatric disorders have been reported to have low
levels of FMRP in the CNS, including schizophrenia, severe depression, and bipolar
disorder (Fatemi et al. 2010). Although FMRP controls the translation of many mRNAs it is
likely there are many cellular mechanisms that control the levels of FMRP, particularly
mechanisms associated with neuropsychiatric disorders. The commonalities across disorders
is an exciting new finding among neurodevelopmental disorders because it means that
therapies developed for one disorder are likely to be helpful for many other disorders (Wang
et al. 2010b). Preliminary evidence described later suggests that the new targeted treatments
for FXS will also be helpful for autism and perhaps other neuropsychiatric disorders.
In this chapter, we will review animal studies leading to targeted treatments and then review
the studies in patients with FXS. Although a number of medications are currently available
that are frequently utilized for treatment for FXS they are not considered targeted treatments
for FXS because they do not reverse the neurobiological abnormalities of FXS but they are
generally helpful for the common symptoms in a variety of neurodevelopmental disorders
(for a more complete review, see Tranfaglia, Chap. 15). Stimulants are effective for
treatment of ADHD in FXS (Hagerman et al. 1988; Berry-Kravis and Potanos 2004;
Hagerman et al. 2009), selective serotonin reuptake inhibitors (SSRIs) are helpful for the
pervasive anxiety in FXS (Hagerman et al. 1994; Berry-Kravis and Potanos 2004; Hagerman
et al. 2009), and atypical antipsychotics are helpful for mood stabilization and treatment of
aggression and irritability (Erickson et al. 2010b). These commonly used treatments have
been reviewed elsewhere (Hagerman et al. 2009). The remaining sections of this chapter
focus on targeted treatments for FXS; these are summarized in Table 17.1.
17.1.1 Developing Treatment Strategies for FXS Based on Fmr1-Knockout Mouse Studies
Mutations in the FMR1 gene that lead to transcriptional silencing and loss of FMRP
expression result in FXS. The Fmr1-Knockout (KO) mouse does not express FMRP,
exhibits many of the phenotypic characteristics of the human FXS condition, and has been
an extremely useful tool to investigate the nervous system abnormalities arising from the
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loss of FMRP, as well as for the development of potential therapeutics for the treatment of
this syndrome. Recent discoveries made from investigations using the Fmr1-KO have given
rise to potential therapeutics for FXS, and in particular for the treatment of intellectual
disability. As will be discussed, a number of approaches have found some success in the
animal model with subsequent human trials. The animal models, to varying degrees, have
led to positive outcomes for anatomical, electrophysiological, and behavioral measures
across the different strategies.
17.1.1.1 Group I Metabotropic Glutamate Receptor Strategy—One of the first
insights into the neurochemical underpinnings of FXS came from work by Bear, Huber, and
colleagues on group I metabotropic glutamate receptors (mGluRs). In the hippocampal field
CA1, activation of mGluR5 leads to long-term depression (LTD), which is seen as a
reduction in synaptic responses. Importantly, LTD triggered by mGluR activation (mGluR-
LTD) requires the rapid translation of preexisting mRNA in the postsynaptic dendrites
(Huber et al. 2000). Huber et al. found in the Fmr1-KO that hippocampal LTD was more
pronounced (greater depression) than in wild types (Huber et al. 2002). This work gave rise
to the mGluR theory of Fragile X which argues that the psychiatric and neurological aspects
of the syndrome are a consequence of an exaggerated response to group I mGluR1/5
activation (Bear et al. 2004); for more details as to role of FMRP in negatively regulating
local protein synthesis, and how the lack of synthesis inhibition leads to exaggerated LTD,
the reader is referred to several comprehensive reviews (Waung and Huber 2009; Berry-
Kravis et al. 2011; Chap. 18). This work has compelled numerous investigations into the
outcomes of blocking group I mGluRs, most particularly the mGluR5 subtype, in the Fmr1-
KO on different aspects of the phenotype that align with the human condition.
Studies aimed at blocking mGluR5 have principally used the selective noncompetitive
antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) (Gasparini et al. 1999). Reducing
mGluR5 function either with MPEP treatment or by lowering mGluR5 levels (~50%) in the
Fmr1-KO has been shown to ameliorate a number of abnormal features in the mouse model
that, to a great degree, reflect the human FXS phenotype. These features in the mouse
mutant and the effects of mGluR5 antagonism/reduction on them are described later.
Dendritic Spine Morphology: Dendritic spine abnormalities have been described in both
FXS (Rudelli et al. 1985; Hinton et al. 1991; Wisniewski et al. 1991; Irwin et al. 2001) and
the Fmr1-KO (Comery et al. 1997; Irwin et al. 2002; Grossman et al. 2006). By and large,
the fragile X mutation results in greater spine density on adult cortical neurons and greater
numbers of spines that have an “immature” profile: There is a lower density of mushroom
shaped spines with large heads, a greater number of longer spines, and excessive filopodia.
In both developing and adult hippocampal neurons, spine abnormalities are present (Braun
and Segal 2000; Antar et al. 2006; Grossman et al. 2006; de Vrij et al. 2008; Bilousova et al.
2009). Correcting these defects in spine morphology and numbers has become a standard
“litmus test” in the field for evaluating the efficacy of drug treatments. Thus far, spine
abnormalities seen in hippocampal neurons in vitro have been rescued with two independent
mGluR5 antagonists, MPEP and fenobam (de Vrij et al. 2008). In addition, reducing
mGluR5 expression in brain normalized spine density on visual cortical neurons in the adult
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animal (Dölen et al.2007). While more work is needed to examine effects on spine
morphology in the adult brain, these data suggest that mGluR5 antagonism in FXS could be
very beneficial.
Protein Synthesis: FMRP binds to mRNAs (including its own) and regulates their
translation within dendrites and spines in response to neural activation (Weiler et al. 1997,
2004) and, in particular, occurs in response to activation by either group I mGluR, (Huber et
al. 2002; Antar et al. 2004; Aschrafi et al. 2005), muscarinic (M1) acetylcholine receptors
(Volk et al. 2007), and possibly other synaptic Gq-linked receptors including dopamine D1
receptors (Wang et al. 2010a). In the Fmr1-KO, levels of synaptic proteins for a number of
FMRP target mRNAs are elevated including MAP1B, PSD95, CaMKII, APP, Arc, and
PP2A, amongst others [reviewed in (Berry-Kravis et al. (2011)]. In vivo treatment of Fmr1-
KOs with MPEP has been shown to increase levels of mRNA granules (levels are reduced in
the mutant as a consequence of heightened translation) indicating that mGluR5 antagonism
can normalize protein synthesis in the KO (Aschrafi et al. 2005). Overall protein synthesis in
Fmr1-KO brain also is reduced by lowering mGluR5 levels by half (Dölen et al. 2007),
further supporting the idea that blockade of this receptor subtype will normalize protein
content in FXS.
Long-term Depression: As described earlier, hippocampal mGluR-dependent LTD is more
pronounced in the Fmr1-KO as compared to wild-type mice (Huber et al. 2002; Hou et al.
2006; Nosyreva and Huber 2006; Sharma et al. 2010); as induction of this type of synaptic
plasticity is dependent on group I mGluR activation, tests of antagonism of this receptor
group have not been conducted. Interestingly though, a recent study by Choi et al. (2010)
showed that chronic treatment (8 weeks) with the group II mGluR antagonist LY341495 in
Fmr1-KOs reduced their level of hippocampal mGluR-LTD to near wild-type levels
suggesting that targeting other mGluRs may also be beneficial. Finally, enhanced LTD has
been reported in Fmr1-KO cerebellum as well (Koekkoek et al. 2005), although group I
mGluR antagonists have not been tested in this system.
Long-term Potentiation: Long-term potentiation (LTP) reflects greater synaptic strength,
and is considered the main cellular substrate thought to underlie learning and memory. In the
Fmr1-KO, deficits in LTP have been reported for a number of brain regions including the
neocortex (Li et al. 2002; Meredith et al. 2007; Wilson and Cox 2007), the piriform cortex
(Larson et al. 2005), the hippocampus (Lauterborn et al. 2007; Shang et al. 2009; Chen et al.
2010), and the amygdala (Zhao et al. 2005; Suvrathan et al. 2010). In the few brain areas
surveyed thus far mGluR5 antagonism by MPEP does not correct this aspect of the
phenotype (Wilson and Cox 2007; Suvrathan et al. 2010), although this drug has been
reported to rescue spontaneous excitatory postsynaptic currents in the Fmr1-KO (Suvrathan
et al. 2010; Meredith et al. 2011). These data suggest that some, but not all, synaptic defects
may be amenable to group I mGluR-targeted intervention.
Prepulse Inhibition: One of the most common clinical features of FXS is heightened
sensitivity to sensory stimulation (Cohen 1995; Miller et al. 1999; Frankland et al. 2004).
Prepulse inhibition (PPI) of an acoustic startle response, a widely used model to study basic
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sensorimotor processing, has been shown to be related to mGluR signaling (Grauer and
Marquis 1999). While PPI is reportedly reduced in humans with the fragile X full mutation
(Hessl et al. 2008), studies in the Fmr1-KO are mixed with one group reporting enhanced
(Frankland et al. 2004) and another group reporting reduced (de Vrij et al. 2008) PPI, albeit
with PPI measurement conducted differently in these two studies. Interestingly, the defect in
the Fmr1-KO’s PPI response reported by de Vrij et al. (2008) was measured via a similar
protocol to that used in humans with FXS and was rescued by MPEP treatment (de Vrij et
al. 2008).
Seizures: A substantial number (~15%) of patients with FXS suffer from epilepsy during
development (Musumeci et al. 1999; Sabaratnam et al. 2001; Berry-Kravis et al. 2010).
While the factors responsible for this hyperexcitability in FXS are poorly understood,
enhanced Gp1 mGluR activation has been shown to induce epilepti-form activity (Ure et al.
2006; Karr et al. 2010). As in the human condition, loss of FMRP in the mouse model
results in a greater tendency towards seizures and, in particular, Fmr1-KOs have a more
excitable audiogenic seizure pathway (Chen and Toth 2001; Yan et al. 2005; Musumeci et
al. 2007), and more protracted hippocampal seizures following kindling (Qiu et al. 2009),
than do wild types. Treatment with MPEP has been shown to suppress both audiogenic and
limbic seizures in the KO (Yan et al. 2005; Qiu et al. 2009), and reducing mGluR5 levels by
50% also significantly attenuated audiogenic seizures (Dölen et al. 2007). Similarly, studies
of the hippocampus have shown that endogenous glutamatergic transmission induces
prolonged synchronized discharges in KOs but not in wild types, suggesting a greater degree
of excitability in the mutant (Chuang et al. 2005). This effect in Fmr1-KOs was mediated by
Group I mGluRs as it was blocked by both mGluR5 (MPEP) and mGluR1 (LY367385)
antagonists. As to the downstream mechanism involved in the induction of prolonged
synchronized discharges, previous work has implicated the extracellular signal-regulated
kinase 1/2 (ERK1/2; a.k.a. MAPK) (Zhao et al. 2004). Inhibition of ERK signaling in the
Fmr1-KO hippocampus with a mitogen-activated protein kinase kinase (MEK) inhibitor also
blocked the prolonged synchronized discharges (Chuang et al. 2005).
Learning: While learning deficits have been difficult to reliably assess in the Fmr1-KO
perhaps due to strain differences, a number of studies have described learning problems for
the mutant in different tasks including Morris water maze (Bakker and Consortium 1994;
D’Hooge et al. 1997; Dobkin et al. 2000), radial maze (Mineur et al. 2002), fear
conditioning (Paradee et al. 1999; Qin et al. 2005), object discrimination (Ventura et al.
2004), odor discrimination (Larson et al. 2008), and eye blink conditioning (Koekkoek et al.
2005). Surprisingly, little work has been done to test the effect of group I mGluR
antagonism on learning in the Fmr1-KO. To date, Dölen et al. (2007) have shown that
genetic reduction of brain mGluR5 levels rescues inhibitory avoidance (extinction) learning
in the Fmr1-KO. While further studies are needed to assess mGluR5 antagonists on this
aspect of the phenotype in mammals, studies in the Drosophila (dfmr) model of FXS have
shown positive effects of MPEP treatment on learning (McBride et al. 2005; Bolduc et al.
2008).
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Motor Behavior: Fmr1-KOs have been reported to have abnormal motor behavior
including displaying hyperactivity (Bakker and Consortium 1994; Mineur et al. 2002; Qin et
al. 2005; Restivo et al. 2005), increased exploratory behavior (Bakker and Consortium
1994), and spending more time in the center of an open field (Yan et al. 2004; Qin et al.
2005). Treatment with MPEP has been shown to reduce center field behavior in the KO to
one indistinguishable from wild type (Yan et al. 2005), but effects of mGluR5 antagonism
on other motor behaviors have not been assessed.
Macroorchidism: As in the human FXS condition, postadolescent male Fmr1-KOs have
enlarged testes (macroorchidism) (Bakker and Consortium 1994; Kooy et al. 1996; Yan et
al. 2004). Neither partial reduction nor full loss of mGluR5 expression in the Fmr1-KO
rescues this aspect of the phenotype (Dölen et al. 2007).
Autism-Like Behaviors: The above studies indicate that Group I mGluR antagonism in
patients with FXS could have substantial effects across a wide range of clinical features in
this syndrome. Importantly though, one aspect of the syndrome that has yet to be addressed
in the mouse model, or with mGluR5 antagonism in particular, is autism. About 30% of
individuals with FXS are diagnosed with autism, a disorder characterized by abnormal
reciprocal social interactions, communications deficits, and repetitive behaviors. While
autistic-like behaviors have yet to be fully investigated in the Fmr1-KO they do display
some social behavioral abnormalities (Mineur et al. 2006; McNaughton et al. 2008). By
comparison, the inbred mouse strain BTBR T + tf/J (BTBR) has been investigated to a
greater extent and reported to have a number of features associated with autism (McFarlane
et al. 2008). Treatment of BTBR mice with MPEP improves some aspects of their behavior
such as reducing repetitive grooming, but does not improve their sociability (Silverman et al.
2010). Further work is needed in both mouse models and human testing to evaluate whether
mGluR5 antagonism is effective in the treatment of autism-related behaviors.
17.1.2 mGluR5 Antagonists in Human Trials
The first trial of an mGluR5 antagonist in patients with FXS, sponsored by Neuropharm
LTD, involved the use of fenobam in 12 adults with FXS given a single dose (Berry-Kravis
et al. 2009). Although the purpose of this single-dose trial was to assess pharmacokinetics
and side effects, there was a positive behavioral response with improved communication and
eye contact in addition to improvement in the PPI deficit which has been documented in
patients with FXS (Hessl et al. 2008). Although this first trial of fenobam was very
promising, further development of fenobam was not pursued by Neuropharm due to
financial challenges.
The next study of an mGluR5 antagonist in adults with FXS was a European trial of
AFQ056 that took place at three centers (Jacquemont et al. 2011). This study was double
blind and included 30 patients with FXS, ages 18–35, who were randomized to AFQ056 or
placebo, underwent dose up titration, 14 days of full dose treatment, and then down titration
(total treatment period 28 days) and then crossed over after a 1-week washout period
between treatment sessions. Although the overall patient cohort did not demonstrate efficacy
of AFQ056 compared to placebo in the primary measures, there was a positive response to
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AFQ056 on the Repetitive Behaviors Scale (RBS-R). In an exploratory analysis it was found
that those patients who were fully methylated (n = 7) demonstrated a significant response to
AFQ056 in the primary outcome measures, the Aberrant Behavior Checklist (ABC), and the
Clinical Global Impression Scale (CGI) in addition to most of the secondary outcome
measures compared to placebo (Jacquemont et al. 2011). This demonstrates a methylation
biomarker for drug response, most likely reflective of clinical response after short-term
treatment in those that are more affected by FXS.
Other mGluR5 antagonists are being assessed currently in multicenter clinical trials
including R04917523 (Roche Pharmaceuticals) and also STX107 (Seaside Therapeutics).
Further study will be needed to know if these agents are efficacious in FXS compared to
placebo.
17.1.2.1 Targeting GABA Receptors—Work on both the mouse and fly models of FXS
demonstrate that they have lower levels of GABA receptors, with the Fmr1-KO exhibiting
clear reductions in the GABA-A subtype in brain (El Idrissi et al. 2005; D’Hulst et al. 2006;
Gantois et al. 2006). In addition, the Fmr1-KO exhibits reduced inhibitory postsynaptic
currents in the amygdala (Olmos-Serrano et al. 2010) and abnormal GABA-A currents in
subicular neurons (Curia et al. 2008), but levels of glutamic acid decarboxylase, the rate
limiting enzyme for GABA synthesis, in brain are mixed (El Idrissi et al. 2009; Olmos-
Serrano et al. 2010). As GABA is the principal inhibitory neurotransmitter of the CNS, the
collective findings indicate that the balance between neuronal inhibition and excitation in
FXS would favor more overall excitation; this conclusion is consistent with the observation
that seizures are more prevalent in FXS than in the general population. Two approaches for
restoring appropriate levels of GABA-mediated inhibition entail use of agonists to either the
GABA-A or GABA-B receptor subtypes. GABA-A agonists act to directly compensate for
the GABA-A subunit deficiencies, whereas GABA-B agonists act presynaptically to block
glutamate release thus decreasing glutamatergic drive in general, but also would be expected
to reduce group I mGluR activation and downstream signaling events. In the Fmr1-KO, the
GABA-A agonists ganaxolone and taurine have been reported to reduce audiogenic seizures
(Kooy et al. 2010) and improve learning in a passive avoidance test (El Idrissi et al. 2009),
respectively. The GABA-B agonist R-baclofen (Arbaclofen; the right-sided enantiomer of
baclofen) also rescues the audiogenic phenotype in the mouse model (Pacey et al. 2009), and
normalizes several behaviors including marble burying and open field locomotor activity
(Paylor 2008). Similarly, studies in the dfmr mutant fly show that a variety of GABA
agonists ameloriate the lethality phenotype from glutamate-containing food,
neuropathology, excessive protein translation, and abnormal courtship behavior (Chang et
al. 2008).
17.1.2.2 Arbaclofen Trials in Individuals with FXS—In addition to animal data
discussed earlier, anecdotal clinical experience suggesting behavioral benefits from racemic
baclofen administered to patients with autism and fragile X in a clinical setting, and data
from TMS studies demonstrating enhancement of cortical inhibition by racemic baclofen
(McDonnell et al. 2007), supported the concept of baclofen as a possible treatment for
humans with FXS. Arbaclofen (R-baclofen) has more potent GABA-B agonist activity,
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leading to development of this molecule for the treatment of FXS. An initial pilot double-
blind placebo-controlled crossover trial of arbaclofen for children and adults with FXS, age
6–40 years, conducted by Seaside Therapeutics, involved 4-week periods of placebo and
active drug treatment for each subject, with drug washout in between treatment periods. This
trial showed benefit for arbaclofen over a placebo in global preference for the treatment
period and clinician global impression, and was particularly evident in the subgroups of FXS
patients with autism, more severe irritable behavior, or more severe social deficits. In the
group with more impairment in social behaviors (ABC Social Withdrawal Score >8),
significant improvement on the ABC Social Withdrawal scale, Vineland Play and Leisure
Scale, and Visual Analog Scale rating for behavior were also seen (Wang et al. 2011), as
well as a significantly increased number of responders (“much” or “very much” improved
on the CGI and a > 25% improvement on the ABC Social Withdrawal subscale) during
arbaclofen as opposed to placebo treatment. There were no significant safety issues and a
very mild side effect profile. Many subjects are continuing treatment though an extension
study, to evaluate the long-term benefits and the toxicity. Anecdotally, many of these
subjects continue to show benefits of treatment and further development of arbaclofen is in
progress with additional clinical trials pending.
17.1.2.3 Ampakines and Targeting Brain-Derived Neurotrophic Factor—The
neurotrophin brain derived neurotrophic factor (BDNF) has been shown in numerous studies
to be a positive modulator of synaptic plasticity. In particular, application of BDNF or
increasing endogenous levels of BDNF production facilitates hippocampal LTP, as well as
memory (Kramár et al. 2004; Minichiello 2009). Recent work has shown that BDNF
corrects hippocampal LTP deficits in several rodent models of diseases or conditions that are
characterized by memory impairment, including those for Huntington’s disease (Lynch et al.
2007; Simmons et al. 2009), middle aging (Rex et al. 2006), and menopause (Kramar et al.
2010). Similarly, BDNF was also tested in the Fmr1-KO to determine if the neurotrophin
could restore hippocampal LTP in the mutant: Using theta burst stimulation (TBS) to elicit
LTP in the hippocampal CA1 region, the Fmr1-KOs were found to have a higher threshold
of induction such that five theta bursts only induced LTP in WT hippocampal slices and not
in Fmr1-KOs. However, in the presence of BDNF (nM) five theta bursts elicited LTP in
Fmr1-KO slices to the same degree as seen in WT slices (Lauterborn et al. 2007). The fact
that BDNF corrected the deficit does not, in and of itself, indicate that BDNF levels are
perturbed in the Fmr1-KO. In fact, protein measures for both BDNF and its high affinity
receptor TrkB in hippocampus were comparable between KOs and wildtypes. However,
recent work by Louhivuori et al. (2011) in the Fmr1-KO has shown that BDNF mRNA is
mis-localized in neocortical and hippocampal neurons suggesting that the site(s) of
neurotrophin release and signaling may be abnormal. Furthermore, Selby et al. (Selby et al.
2007) have reported that TrkB levels are higher in a subgroup of neocortical GABAergic
interneurons suggesting that cell-type specific alterations in the receptor may be present in
FXS. Further work is needed to determine if disturbances in BDNF release, and thus
availability at the synapse, are present in the Fmr1-KO and if the responsivity of the TrkB
receptor is abnormal.
Hagerman et al. Page 8






















One would predict that drugs that augment BDNF content in brain likely facilitate learning
and memory. A class of drugs that does both (increases BDNF expression and enhances
learning) is the positive AMPA receptor modulators, also known as “ampakines.”
Ampakines enhance fast, excitatory transmission at central synapses (Staubli et al. 1994a,
b), and produce a variety of acute effects including lowered thresholds for LTP and
accelerated learning in animals ((Lynch and Gall 2006) for review); effects on memory
encoding in humans also have been reported (Ingvar et al. 1997). Ampakines also increase
the expression of BDNF in hippocampal and neocortical neurons, both in vitro and in vivo,
with elevated levels of BDNF lasting for days following a single injection/treatment
(Lauterborn et al. 2000; Legutko et al. 2001; Lauterborn et al. 2003, 2009). Importantly,
ampakine-induced increases in BDNF are neuroprotective in models of insult (Destot-Wong
et al. 2009; Jourdi et al. 2009a), and can facilitate both LTP (Rex et al. 2006; Simmons et al.
2009; Kramar et al. 2010) and behavior (Simmons et al. 2009) in different animal models of
cognitive impairment. Thus, the overall ampakine strategy for the treatment of cognitive
impairment in FXS should be viewed as having two facets: an immediate effect of the
ampakine on AMPAR function and a more protracted effect on synaptic plasticity through
longer term effects on BDNF content. As expression of AMPA receptors is reduced in many
brain regions of the Fmr1-KO (Li et al. 2002; Muddashetty et al. 2007; Suvrathan et al.
2010), direct positive modulation of residual receptors could be very beneficial for
enhancing glutamatergic-mediated synaptic plasticity. While studies are ongoing to assess
the ampakines for effects on LTP, spine morphology, and cognitive behavior in the Fmr1-
KO, it is important to note that the ampakines effectively increase BDNF expression in this
animal model (Lauterborn and Gall 2004) making it possible to test the long-term effects of
enhanced neurotrophism on its phenotype.
Finally, a significant finding in the Fmr1-KO is the enhanced internalization of AMPA
receptors in this mutant by mechanisms engaged by at least two different receptors, mGluR5
and dopamine D1 (Nakamoto et al. 2007; Wang et al. 2010a). Importantly, mGluR5
antagonism has been shown to block the internalization of the AMPARs (Nakamoto et al.
2007). Thus, it seems reasonable to conclude that combinational therapy with both an
mGluR5 antagonist, which increases AMPAR levels at the synapse and reduces exaggerated
protein synthesis, and an ampakine, which facilitates synaptic plasticity and enhances
neurotrophism, could be particularly efficacious as a treatment strategy for the cognitive and
behavioral problems in FXS.
17.1.2.4 Use of Ampakines in FXS—A single human trial has been completed with
CX516 (Cortex Phamaceuticals), a direct AMPA receptor positive modulator known to
increase LTP and raise BDNF levels (Jourdi et al. 2009b). This was a double-blind placebo-
controlled trial of effects of CX516 on the safety and the cognitive and behavioral efficacy
measures carried out in a cohort of 49 individuals with FXS (Berry-Kravis et al. 2006). The
primary outcome measure was a z-score for memory across several verbal and nonverbal
memory tasks. Conceptually, it was thought the CX516 would help compensate or correct
the AMPA receptor deficit resulting from mGluR pathway overactivity. Realistically,
CX516 is a very weak ampakine and provides only weak BDNF induction, and thus no
improvement was seen in the primary outcome measure of memory, nor were any other
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behavioral or cognitive improvements observed across the full subject group. Improvement
in global functioning was seen in the subgroup of five patients co-treated with an
antipsychotic (known to potentiate ampakine activity), relative to the four patients on
placebo and an antipsychotic. This suggests that a more potent ampakine molecule might be
successful in treating FXS; however, such molecules have not yet come to clinical trials.
Although this trial did not produce the desired improvement in functioning, there were no
major safety issues, providing encouragement for future use of more potent AMPA
activators in the FXS population. Further, this trial was the first to demonstrate that large
fairly intensive phase II clinical trial could be successfully performed in groups of subjects
with FXS, with high completion rates for study procedures.
17.1.2.5 The Dopaminergic System and Stimulants—Individuals with FXS often
display hyperactivity, attention deficit, and lack of impulse control (Hagerman and
Silverman 1991). Dysfunction in frontal-subcortical circuits (i.e., reduced dopaminergic
drive) is thought to give rise to these types of behavior (Hjalgrim et al. 1999), and stimulants
that modulate forebrain dopaminergic tone correct them (Solanto 2002). Consistent with
this, recent work by Fulks et al. (2010) demonstrated that the Fmr1-KOs have reduced
extracellular dopamine levels in striatum. Increased dopamine turnover in the cortical
regions, the striatum, and the hippocampus also has been reported for the KO (Gruss and
Braun 2004). In addition, dopamine receptor 1 (D1) signaling is impaired in both the
striatum and the prefrontal cortex of the mutant, and treatment of Fmr1-KO mice with the
D1 receptor agonist SKF81297 partially reversed their hyperactive locomotor activity and
enhanced their motor function on the rotarod apparatus (Wang et al. 2008a). The
psychostimulant amphetamine has also been shown to elicit a greater increase in dopamine
release in the prefrontal cortex of Fmr1-KOs as compared to wild-type mice, and improved
their ability to discriminate objects (Ventura et al. 2004), suggesting that stimulants may be
useful for restoring some balance in dopaminergic tone in forebrain and improving behavior
in FXS.
17.1.2.6 Human Studies of Stimulants and Aripiprazole in FXS—There has only
been one controlled trial of stimulants in children with FXS and it demonstrated that two-
thirds of the patients responded well to the stimulant compared to the placebo (Hagerman et
al. 1988). Stimulants are widely used now in children with FXS who are 5 years or older and
the effect is generally positive with improvement in hyperactivity and attention (Amaria et
al. 2001; Berry-Kravis and Potanos 2004; Hagerman et al. 2009). Occasionally on a higher
dose greater activation or a lower number of verbalizations can be problematic but
stimulants are usually well tolerated. A negative response to stimulants in a patient under 5
years of age should not deter a trial after 5 years since this drug class is more likely to be
tolerated and effective after age five.
Although aripiprazole is a treatment directed primarily at behavior rather than specific
molecular mechanisms, it could be theoretically targeted to dopamine deficits described in
the fmr1 knockout mouse (Wang et al. 2008a, b), given its dopamine agonist activity at
lower doses. Apipirazole has shown good success when used empirically in FXS clinic
populations (Berry-Kravis and Potanos 2004; Hagerman et al. 2009) and resulted in
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improvement in the ABC Irritability score, other ABC subscores, and additional behavioral
rating scales in 15 participants with FXS treated in a very recently completed open-label
trial (Erickson et al. 2010b). Initiation of a double-blind placebo-controlled trial of
aripiprazole is planned.
17.1.2.7 Targeting Proteins that Regulate the Spine Actin Cytoskeleton—The
spine actin cytoskeleton is a dynamic network that supports the shape, and ultimately the
function, of the postsynaptic structure. There are numerous proteins and signaling pathways
that act to regulate the actin cytoskeleton including the Rho GTPases, and mutations in a
number of these proteins have been associated with different forms of mental retardation
[reviewed in (van Galen and Ramakers 2005)]. Recent work in Drosophila has shown that
dfmr (the fly homologue of FMRP) binds to the mRNA encoding the small Rho GTPase
dRac (Lee et al. 2003), suggesting that FMRP regulates proteins critical to actin remodeling.
Rac signals through its downstream effector p21-activated kinase (PAK), a family of serine–
threonine kinases comprised of at least three members, PAK1, PAK2, and PAK3. The Rac–
PAK pathway recently has been shown to be important for the stabilization of newly formed
actin filaments that occur following TBS (Rex et al. 2009). Although loss-of-function
mutations in the PAK3 gene are associated with non-syndromic X-linked mental retardation
(Allen et al. 1998; Bienvenu et al. 2000), recent work from Hayashi and colleagues (2007)
has suggested that excessive PAK activity in Fmr1-KOs may be an underlying cause of the
dendritic spine abnormalities. In particular, these authors demonstrated that spine
abnormalities in neocortex were partially ameliorated in Fmr1-KOs that expressed a
dominant negative PAK transgene in the forebrain (Hayashi et al. 2007). Likewise, cortical
LTP was fully restored in the Fmr1-KO by reduced PAK expression. Finally, several
behavioral abnormalities, including locomotor activity, stereotypy, anxiety, and trace fear
conditioning, in the KOs also were ameliorated to some degree by the dominant negative
PAK transgene. These data suggest that inhibition of PAK activity could be a potentially
interesting therapeutic target for aspects of the FXS phenotype. To this end, PAK inhibitors
are being developed and in initial testing have shown that they correct spine defects and
restore LTP in the neocortex (Vollrath et al. 2010).
With regard to the PAK inhibitors, it is important to note that systemic use of these
compounds may still only result in regionally selective effects in brain: Although Hayashi et
al. were able to attain reduced PAK levels in both the neocortex and the hippocampus the
effect on dendritic spine features was only observed in neocortex (Hayashi et al. 2004).
Moreover, recent work by Chen and colleagues (2010) in the Fmr1-KO hippocampus
demonstrated that the physiological activation of both Rac and PAK in spines is deficient
and, consistent with this, the newly polymerized spine actin that occurs following LTP-
producing stimulation fails to properly stabilize. These data suggest that the consequence of
FMRP loss on RAC–PAK pathway signaling may be different between the cortex and the
hippocampus, and that the use of PAK inhibitors may be regionally effective for certain
aspects of the FXS phenotype. Evaluation of the impact of these compounds on the different
forms of memory (i.e., those ascribed to hippocampus versus other structures) will be
particularly interesting.
Hagerman et al. Page 11






















17.1.2.8 Targeting Other Intracellular Signaling Pathways: Phosphatase and
Kinase Inhibitors—Several signaling pathways that regulate protein translation are
perturbed in the Fmr1-KO. In particular, mGluR-dependent translation occurs through two
major signaling pathways, the ERK–MAPK and PI3 Kinase-mTOR pathways, with
convergence on the translation initiation (eIF4F) complex [reviewed in(Waung and Huber
2009)]; inhibition of either PI3 kinase, mTOR, ERK, or translation initiation itself prevents
mGluR-LTD (Huber et al. 2000; Gallagher et al. 2004; Hou and Klann 2004). Studies in the
Fmr1-KO have shown that the activation of both ERK and mTOR is misregulated (Kim et
al. 2008; Weng et al. 2008; Sharma et al. 2010), consistent with the observation that protein
synthesis in the mutant is aberrant. Moreover, other proteins that control gene expression
and other cellular processes are also misregulated in the KO including glycogen synthase
kinase-3β (GSK3β) (Min et al. 2009; Yuskaitis et al. 2010a). As such, a number of studies
have targeted these systems (amongst others) and the results for specific drugs and/or targets
are encouraging.
Phosphatase Inhibitors: Weng et al. showed that the phosphorylation of ERK in both
neurons and thymocytes of Fmr-1 KOs, and in lymphocytes from peripheral blood of
individuals with FXS, is delayed (Weng et al. 2008). Kim et al. (2008) also demonstrated
that Group I mGluR-dependent activation of the ERK pathway in the Fmr1-KO is abnormal.
Specifically, following mGluR1/5 stimulation ERK is phosphorylated in wild-type cortical
synaptoneurosomes but dephosphorylated in KO cortical synaptoneurosomes (Kim et al.
2008). These results suggest that in response to synaptic stimulation there is aberrant
activation of phosphatases in Fmr1-KO synapses. In agreement with this, both protein
phosphatase 2A (PP2A) and tyrosine phosphatase were found to be overactivated after
mGluR1 and mGluR5 stimulation, respectively, resulting in the rapid deactivation of ERK
in Fmr1-KO samples. Pretreatment with a PP2A blocker, however, fully restored ERK
activation in Fmr1-KO synaptoneurosomes. The consequence of overactive phosphatases
and a misregulated ERK pathway in FXS could be multifold as the MAPK/ERK pathway is
involved in many cellular processes. However, it is important to note that not all aspects of
the FXS phenotype may be ameliorated by facilitating ERK activation as Chuang et al.
(2005) showed that inhibition of ERK signaling in the Fmr1-KO was beneficial for
controlling seizure-like activity.
PI3K Inhibitors: Recent work by Gross et al. (2010) has shown that PI3K activity, and
downstream signaling to Akt, is markedly increased in Fmr1-KO synapses (Gross et al.
2010). Interestingly, this elevation in PI3K activity is dependent upon the absence of FMRP
but not on the presence of group I mGluRs, although mGluR5 antagonism corrected it
(Gross et al. 2010). Antagonism of PI3K signaling with two different drugs, LY294002 and
wortmannin, rescued excessive synaptic translation in the KO (Gross et al. 2010); treatment
with rapamycin, which inhibits the PI3K downstream signaling molecule mTOR, also
reduced translation in the KO and is in line with the observation of increased
phosphorylation and activity of mTOR in the absence of FMRP (Sharma et al. 2010).
Finally, the same group showed that treatment of Fmr1 knockout neurons in culture with the
PI3K inhibitor LY294002 in vitro reduced AMPAR endocytosis and normalized protrusion
(including spines and filopodia) density in Fmr1-KO neurons to WT levels (Gross et al.
Hagerman et al. Page 12






















2010). These data are intriguing in that they further support the idea of selectively targeting
the PI3K-mTOR pathway for the treatment of FXS. Currently, inhibitors of this pathway are
being investigated in preclinical models of cancer with some success (McMillin et al. 2009),
suggesting the possibility that selective compounds could be available for testing in other
disorders such as FXS in the future.
GSKβ Inhibition and Lithium: Lithium is principally used to treat mood disorders and,
although the exact mechanism is not understood, likely improves behavior through
modulatory effects on various brain chemical systems including serotonin, dopamine, and
the neurotrophin BDNF [reviewed in (Bschor et al. 2003; Beaulieu and Caron 2008; Gold et
al. 2010)]. In recent years, work has more directly linked the effect of lithium to inhibition
of GSK3β, a serine/threonine protein kinase, which in turn promotes β-catenin-dependent
gene expression (Wada 2009). Work by Jope and colleagues has shown that the inhibitory
form of GSK3β is reduced in the Fmr1-KO brain, liver, and testes, suggesting that this
kinase is constitutively overactive in the mutant, and that lithium treatment normalizes these
measures (Min et al. 2009; Yuskaitis et al. 2010a, b). Furthermore, lithium treatment
recently has been shown to normalize levels of activated ERK (Venkitaramani et al. 2010),
indicating that this drug is having effects across several protein synthesis-dependent
pathways. In addition, recent work by Choi and colleagues demonstrate that lithium can
restore normal mGluR-dependent LTD (Choi et al. 2010). Finally, lithium has been shown
to reverse a number of behavioral abnormalities in the Fmr1-KO including open field
hyperactivity (Min et al. 2009; Liu et al. 2010; Yuskaitis et al. 2010b), deficits on a social
interaction task [(Liu et al. 2010; Mines et al. 2010), learning deficits (Liu et al. 2010;
Yuskaitis et al. 2010b), anxiety (Liu et al. 2010; Yuskaitis et al. 2010b), novel object
recognition (Venkitaramani et al. 2010), audiogenic seizures (Min et al. 2009), as well as
dendritic spine shape (Liu et al. 2010), and macroorchidism (Yuskaitis et al. 2010a). Other
GSK3 β inhibitors such as SB-216763 have been shown to reverse a number of these
phenotypes as well (Min et al. 2009). Importantly though, the effects of GSK3β inhibitors
and mGluR5 blockers are not additive, providing strong evidence that excess GSK3β
activity is a direct consequence of excessive mGluR activity (Min et al. 2009).
17.1.2.9 Human Trials of Lithium in FXS—Although a number of intracellular
treatment targets have been proposed, including lithium, PI3K inhibitors, GSK3β inhibitors,
and PAK inhibitors, in most cases safe and available agents acting on these targets are not
yet developed for use in humans. One exception is lithium, for which the preclinical findings
in the dfmr mutant fly and fmr1 knockout mouse, as described earlier, suggested promise of
therapeutic benefit. Lithium may attenuate activation of the phospholipase C (PL-C)
signaling pathway by inhibiting phosphatidyl inositol (PI) turnover (Berridge 1993), and
clearly inhibits GSK3β activity (Min et al. 2009; Yuskaitis et al. 2010b) which would
decrease phosphorylation of ERK and multiple signaling molecules that regulate translation;
all of these effects would theoretically lead to reduction of translational activation. Given
that lithium treatment does in fact normalize levels of activated ERK and GSK3β in the fmr1
knockout (Venkitaramani et al. 2010), it appears that the main effect of lithium in the fmr1
knockout is to reduce excessive GSK3β activity with resultant reduction in excessive ERK-
mediated translation; however, lithium may also directly increase surface expression of
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AMPA receptors (Du et al. 2010) and reduce excess MAP1B activity (Owen and Gordon-
Weeks 2003).
Although lithium has been used for some time to treat mood instability and aggression in
FXS (Berry-Kravis and Potanos 2004; Hagerman et al. 2009; Wang et al. 2010b), only
anecdotal information on effectiveness existed, prior to a pilot proof-of-concept study
initiated by Berry-Kravis et al. (2008a, b) to evaluate the strategy of inhibition of mGluR-
activated translational signaling pathways as a treatment for FXS, by systematically
exploring the effects of short-term (2 month) treatment with lithium on a broad range of
phenotypes including behavior, cognition, and biophysical measures in a small cohort of
subjects with FXS. In addition, since ERK (extracellular-signal regulated kinase) was shown
to have a reduced rate of activation in the fmr1 knockout and in lymphocytes from humans
with FXS (Weng et al. 2008), ERK activation was explored as a potential biomarker for
effects of lithium on cellular signaling and more generally as a model for measuring changes
in signaling during treatment with agents that may impact receptor-activated translational
regulatory pathways. In this pilot open-label trial in 15 patients with FXS (Berry-Kravis et
al. 2008a), lithium treatment resulted in a significant improvement in behavior as was seen
in on the Total Aberrant Behavior Checklist-Community Edition (ABC-C) Score, and the
Hyperactivity, Inappropriate Speech, and Lethargy (Social Withdrawal) subscales of the
ABC, the Maladaptive Behavior subscore from the Vineland Adaptive Behavior Scale
(VABS), a parent visual analog scale for target behaviors, and the Clinical Global
Impression (CGI) Scale. Improvement in verbal memory on the RBANS List Learning task
was also demonstrated in addition to normalization of abnormal ERK phosphorylation rates
in lymphocytes (Berry-Kravis et al. 2008a, b). There were no major side effects but
polydipsia and polyuria were seen relatively frequently as expected, and there were a few
subjects with abnormal thyroid measurements on lithium. A subgroup of 11 subjects
continued on lithium for a year with persistent improvements in behavior on the ABC-C and
VABS, and ongoing normalization of the ERK activation biomarker (Berry-Kravis,
unpublished data), suggesting the behavioral improvements were less likely to be placebo
effects. These data indicated that further studies with a placebo-controlled trial would be
indicated, however such studies have not yet been carried out, partly due to concerns about
the chronic toxicity of lithium, but also related to hope that less toxic mechanism-based
treatments will be available soon.
17.1.2.10 Minocycline and Metalloproteinases—Minocycline is a broad-spectrum
tetracycline analogue commonly used to treat acne and other skin diseases. Interest in this
drug as a potential therapeutic for CNS disorders began with select studies showing that
minocycline was neuroprotective in several mouse models of neurodegenerative disorders
including Huntington’s disease (Chen et al. 2000) and Alzheimer’s disease (Choi et al.
2007). Recently, minocycline was tested in the Fmr1-KO for effects on hippocampal
dendritic spine development and behavior (Bilousova et al. 2009). Bilousova et al. (2009)
found that minocycline promotes the maturation of hippocampal dendritic spines in young
neurons. Specifically, minocycline treatment of cultured Fmr1-KO hippocampal cells
resulted in a greater proportion of mushroom shaped spines, thought to reflect more mature
spines. While there was no effect of treatment on spine length or density, minocycline did
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reduce the number of filopodia-like protrusions. Further, minocycline treatment of nursing
dams beginning at time of birth for 1 week increased the proportion of hippocampal spines
with larger heads and reduced the number of filopdia in the Fmr1-KO pups. While these
findings are very encouraging and indicate that treatments with this drug could begin very
early in development, tests of minocycline on other aspects of the phenotype including
examination of the neocortex where the spine abnormalities are greater and persist through
adulthood will be very important.
The mechanism(s) by which minocycline “normalizes” the maturation of hippocampal
spines is not known but evidence suggests that it could be through regulation of matrix
metalloproteinases (MMPs), which are zinc-dependent endopeptidases that degrade
extracellular matrix proteins. Treatment of wild-type hippocampal neurons with either
MMP-7 or MMP-9 results in a more immature dendritic spine phenotype (more filopodia
and fewer mushroom-like spines) (Bilousova et al. 2006, 2009), indicating that aberrant
MMP levels could give rise to abnormal spine morphologies. Consistent with this
observation, active MMP-9 levels were found to be greater in hippocampal lysates of 1-
week-old Fmr1-KO mice versus wild types (Bilousova et al. 2009). These data suggest that
reducing MMP activity could help to normalize spine morphology. As minocycline and
other tetracyclines are well known to inhibit the expression of MMPs [reviewed in (Griffin
et al. 2010)], and mincycline treatment of Fmr1-KO pups reduced MMP-9 activity
(Bilousova et al. 2009), it is likely that the spine effects described by Bilousova and
colleagues could be due in part to the inhibition of an overactive enzymatic process.
Finally, Bilousova et al. (2009) also tested the effects of minocycline on several behavioral
measures for the Fmr1-KOs; drug was given to nursing dams beginning at birth for 21 days
and the pups were tested at 3 weeks of age. Using the elevated plus maze, the time spent in
the open arm was used as an indicator of anxiety (less time = more anxious). Minocycline-
treated Fmr1-KO mice spent more time in the maze’s open arms as compared to nontreated
mutants, indicating that the drug reduced their anxiety. Using the Y maze to examine
hippocampal dependent memory, the investigators also found that minocycline treatment
facilitated the Fmr1-KO’s strategic exploratory behavior in the task. Overall, these findings
indicate that minocycline could be a potential therapeutic for the treatment of cognitive
impairment in FXS.
17.1.2.11 Human Trials of Minocycline—After publication of the Bilousova et al.
(2009) report, numerous families began using minocycline in their children with FXS as a
targeted treatment. Utari et al. (2010) surveyed 50 families who utilized minocycline in their
children or adults with FXS for at least 2 weeks to 20 months (mean duration 3.5 mo).
Seventy percent of individuals with FXS (43 males and 7 females mean age 13.3 years; SD
6.2 years) had a positive response to minocycline with improvements in language, behavior,
and/or cognition as judged by the parents. Although this was not a controlled trial it
suggested that further studies of minocycline are warranted for treatment of FXS. Paribello
et al. (2010) reported positive effects in an open trial of minocycline in boys with FXS 13
years and older. Currently, a controlled trial of minocycline is taking place at the MIND
Institute for children 3.5 years to 16 years with FXS. So far the trial has not demonstrated
significant side effects and the analysis of efficacy will be carried out in 2011.
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17.1.2.12 Antioxidants: Melatonin and Vitamin E—Results of studies using the
Fmr1-KOs have suggested that antioxidants such as melatonin and vitamin E could be
beneficial for aspects of the FXS phenotype. Melatonin is a hormone secreted by the pineal
gland that acts to regulate the body’s circadiam rhythm, in addition to other hormones.
Melatonin is also a strong antioxidant and has been shown to be neuroprotective in animal
studies (Singhal et al. 2010). Evidence for oxidative stress in the Fmr1-KO has been
reported (el Bekay et al. 2007; Romero-Zerbo et al. 2009); for example, the mutants display
reduced glutathione levels (in brain) and elevated lipid peroxidation (in brain and testes).
Treatment with melatonin for 1 month normalized these biochemical measures in the mutant
(Romero-Zerbo et al. 2009). In addition, measures of aberrant motor and learning behaviors
as well as anxiety in the Fmr1-KOs also were normalized by melatonin treatment (Romero-
Zerbo et al. 2009). Similarly, treatment of Fmr1-KOs with the strong antioxidant/free radical
scavenger vitamin E (alpha-tocopherol) with or without N-acetyl L cysteine (NAC) has been
shown to normalize oxidative stress markers, testicular size, and behavior (learning, anxiety)
(de Diego-Otero et al. 2008). While these data suggest that melatonin and vitamin E could
be useful for FXS, particularly as part of a combinational treatment strategy with another
drug approach, for it is important to note that melatonin has a very short half-life.
Consequently, synthetic melatonergic agonists may be more effective (Hardeland 2010).
17.1.2.13 Human Trials of Melatonin and Other Antioxidants—A controlled study
of melatonin’s effect on sleep has been carried out in six children with FXS, one with the
premutation and in five children with ASD between the ages of 2 and 15.25 years (SD 3.6)
(Wirojanan et al. 2009). This study lasted 4 weeks with a crossover design between
melatonin and placebo. Children treated with melatonin demonstrated a significant increase
in mean night sleep duration, a decrease in mean sleep onset latency, and an earlier sleep
onset time compared to placebo. Dysregulated sleep occurs in 32–77% of patients with FXS
(Richdale 2003; Kronk et al. 2010). However, these sleep problems are universal in many
neurodevelopmental disorders including autism (Richdale 1999). Other controlled trials of
melatonin have also been helpful for ASD (Garstang and Wallis 2006). It is also possible
that the therapeutic effects of melatonin are related to its antioxidant effects and ability to
normalize synaptic connections in the KO mouse (Romero-Zerbo et al. 2009). Although
other antioxidants such as omega 3 fatty acid, vitamin C, vitamin E, and NAC have been
utilized by many families often routinely there have been no controlled studies of their use.
An exception to this is the controlled study of L acetylcarnitine (LAC) carried out by Torelli
and colleagues (2008) in 63 males with FXS and ADHD treated for 1 year in a controlled
parallel study of LAC (20–50 mg/kg/day up to 1,000 mg/day) versus placebo. Fifty six
patients completed the study and there was a significant improvement in ADHD symptoms
on the Conners Global Index Parents scale and also in behavior and socialization on the
Vineland Composite and Socalization Scale with LAC compared to a placebo.
17.1.2.14 Human Trials of Donazepil and Other Agents—Other agents acting at an
array of receptors have undergone exploratory study in groups with FXS [reviewed in
(Berry-Kravis et al. 2011)]. These include donazepil, an anticholinesterase which raises
acetyl choline in brain and is extensively utilized for maintenance of cognitive function in
Alzheimer’s disease. Donazepil showed promise for treatment of behavior and social
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function in an open-label trial in participants with FXS and now is being studied in a larger
placebo-controlled trial (clinicaltrials.gov). A small open-label study of memantine, an
NMDA antagonist, in six individuals with FXS demonstrated modest clinical benefit on a
CGI in 4/6 patients, but lack of improvement on behavioral rating scales, and several
patients developed substantial irritability that limited treatment (Erickson et al. 2009). An
open-label study of riluzole, a sodium channel blocker and glutamate uptake activator that
indirectly decreases glutamate receptor activity, showed overall behavioral improvement in
only one subject of five patients with FXS treated, although ERK activation rates
normalized and there was a suggestion of improvement specifically in hyperactivity
symptoms (Erickson et al. 2010c).
Anecdotal treatment experience with three adults with FXS treated with acamprosate,
demonstrated improvement in language and behavior in all patients (Erickson et al. 2010a).
Acamprosate is a drug approved for assisting with alcohol withdrawal that most likely
interacts with multiple receptors but primarily may exert effects by acting as a mixed
agonist/antagonist at NMDA receptors and activating GABA-A receptors with possibly
inhibitory effects at group I mGluRs (Erickson et al. 2010a). One patient had significant
gastrointestinal side effects that are often seen with acamprosate.
Cells from the fmr1 knockout mouse and from individuals with fragile X show reduced
cAMP production (Berry-Kravis et al. 1995; Kelley et al. 2007; Chen et al. 2010) which is
dependent on FMRP levels (Berry-Kravis and Ciurlionis 1998). Likewise adenylate cyclase
activity modulates mGluR-mediated regulation of FMRP activity (Wang et al. 2008a, b).
Although the mechanism through which FMRP regulates cAMP production is not known,
FMRP is known to bind adenylate cyclase subunit mRNAs (Darnell et al. 2011). Because of
the reduction in cAMP production in FXS tissue, treatment with phosphodiesterase
inhibitors such as rolipram has been proposed, however no preclinical work has yet been
done in this area.
17.1.2.15 Genetic Manipulations—A few studies have attempted to correct the
phenotype in the Fmr1-KO by genetic manipulation. The approach used with some success
was either through the reduction of mGluR5 levels (see above) or by expressing FMRP de
novo in the Fmr1-KO (Peier et al. 2000; Gantois et al. 2001; Musumeci et al. 2007; Zeier et
al. 2009). Expression of FMRP in the Fmr1-KO rescued a number of the phenotypes
including normalizing hippocampal LTD (Zeier et al. 2009), macroorchidism (Peier et al.
2000), reducing anxiety (Peier et al. 2000), and reducing audiogenic seizure susceptibility
(Musumeci et al. 2007). While gene and/or stem cell therapy for neurological disorders is
still in its early phase and has a number of issues, these studies are encouraging and suggest
that this approach could correct the FXS phenotype (for comprehensive reviews see Chaps.
2 and 6).
17.1.2.16 Clinical Trial Design and Associated Hurdles in FXS—Although an
ever-increasing number of neuronal targets for treating the underlying disorder in FXS are
emerging, and have prompted early translational work, there are still many issues regarding
optimal trial design and how to best demonstrate treatment effects in a clinical trial setting,
in the absence of good models for cognitive treatment trials for any neurodevelopmental
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disorders [reviewed in (Berry-Kravis et al. 2011)]. FXS, in fact, serves as a good model to
develop such designs, particularly because FXS is a single genetic disorder in which all
affected individuals have the same cellular defect as the primary cause of their brain
disorder, a mouse model is available, information on the synaptic function of FMRP in brain
is known, and aspects of FXS model more common disorders likely to have mechanistic
overlap, including autistic spectrum disorders and learning disabilities.
Trial design issues that need to be resolved for each targeted treatment trial in FXS include:
(1) length of placebo treatment and whether to use crossover designs or open-label
extensions to ensure everyone gets a chance at active treatment and increased recruitment;
(2) lack of information on optimal dosing and whether to determine this through dose
escalation or flexible dosing within or between subjects or multiple fixed-dose arms; (3)
how to best detect side effects in cognitively impaired individuals who may not be able to
discuss their symptoms; (4) the most appropriate age range to study treatment effects,
balancing concerns about safety that dictate studies in adult trials initially, with the
possibility that studies at younger ages may be indicated even if there are minimal effects in
older individuals, because much more significant results may be seen by treating the
underlying disorder in young children who are not as advanced in the process of brain
development, and are still in school; (5) understanding of the length of treatment needed to
impact brain wiring and demonstrate measurable cognitive improvement; (6) drug
formulation and how to best deliver drugs to younger children and individuals with
difficulty swallowing pills due to coordination issues; (7) inclusion of females and mosaic
individuals, and whether to analyze their responses separately, as individuals with FMRP
present in a fraction of cells may have different dosing ranges, responses, and toxicities; (8)
whether to allow baseline medications and the balance between the need to analyze
treatment effects in the absence of medication interactions, problems with recruitment and
patient deterioration if baseline medications have to be weaned, and the importance of
demonstrating that new targeted treatments can actually improve symptoms even when the
best available symptomatic regimen is already in place; (9) the numbers of study visits and
travel issues for a relatively rare disorder in which subject numbers are limited and
participants may travel a distance to get to a trial site; and (10) the problem of the lack of
validated, sensitive behavioral outcome measures, the lack of well-defined cognitive
outcome measures, and the lack of biomarkers known to correlate with functional status in
FXS.
The design and validation of outcome measures for clinical trials in FXS and other
neurodevelopmental disorders represents the most significant hurdle in trial design for
targeted treatments. The choice of optimal outcome measures has been difficult because of
the need to test a broad range of abilities so that there is not too much floor or ceiling effects
with high- or low-functioning individuals, issues with co-operation and variable
performance, the general lack of information on reproducibility of measures for the
population being studied, and because for measures that would appear to quantify core
defects, there is insufficient data available on whether they correlate with quality of life or
true functional improvement. Only a subset of outcome measures utilized in recent trials
have shown good feasibility and validity (Berry-Kravis et al. 2006, 2008a, b, 2009). Thus,
recently investigators have begun to develop templates for pretrial feasibility,
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reproducibility, and validity assessment (Berry-Kravis et al. 2008a, b; Hessl et al. 2008;
Knox and Berry-Kravis 2009; Scaggs et al. 2011). The choice of outcome measures must
also balance the use of standard accepted behavioral measures with precedent for use in drug
registration/FDA approval, which are generally caregiver rating scales (such as the ABC),
versus use of novel measures (Hessl et al. 2008; Knox and Berry-Kravis 2009; Scaggs et al.
2011) that are more quantitative and may objectively measure core phenotypes (such as eye
tracking or PPI), thus advancing treatment science, but have no precedent for registration
and are not yet known to predict a specific functional outcome.
A recent series of NIH-sponsored meetings (2009) aimed at developing a consensus about
optimal outcome measures for clinical trials in FXS has resulted in some recommendations
about best choice of currently existing measures, validation needs for existing measures,
optimal additional measures that need to be developed, and the work needed to develop
these. No one behavioral rating scale was felt to capture the range and character of problem
behaviors typically observed in individuals with FXS, and the development and validation of
a fragile X-specific behavioral scale has been suggested. As initial work in preparation for
development of such a scale, ABC ratings have been collected from multiple sites and
subjected to factor analysis for FXS relative to age and gender. This early work has
indicated that the factor structure of ABC subscales and the number of items incorporated
into the scale (which was developed for individuals with general cognitive impairment and
has been used extensively in autism) should be modified for good validity in FXS (Hessl et
al. 2010).
Several years ago the Fragile X Clinical and Research Consortium (FXCRC) was created to
help ensure state-of-the-art care delivery to meet the needs of individuals with FXS in North
America and facilitate large-scale research efforts and clinical trials. This organization is
developing structure for collaboration of FXS clinics worldwide, in preparation for large
multisite clinical trials that will be necessary for regulatory approval of targeted treatments.
17.1.2.17 Combining Targeted Treatments with Educational Interventions—
Medications alone will not reverse the phenotype of those with FXS because the learning
that has occurred throughout life has to be recovered also. The targeted treatments will
improve synaptic connections but cognitive remediation needs to take place to strengthen
these connections and remediate the lost learning unless treatment is started right after birth.
This is pertinent to adults who are initiated into targeted treatments because they are out of
school and not necessarily in a learning environment. Basic abilities such as reading or
writing must be addressed in learning paradigms and often a tutor is an expense that cannot
be afforded by many families. Therefore, computer learning programs can be utilized and
targeted treatment studies should begin to address the efficacy of learning both with and
without targeted treatments.
An example of a learning computer module is the Cogmed program developed by Torkel
Klingberg (Cogmed Cognitive Medical Systems AB, Stockholm, Sweden) for the training of
working memory. Working memory (WM), defined as the ability to temporarily store and
manipulate information for some purpose (Baddeley 2000), is instrumental for a plethora of
daily activities such as keeping track of goals and instructions and planning the next course
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of action based on current conditions. From a psychometric standpoint, WM can be easily
and objectively measured (e.g., through simple span tasks incorporating a simultaneous
processing element, such as mentally reordering a series of digits/letters or pattern of blocks)
with tasks that most people are capable of performing with varying degrees of success. It is
therefore a natural target for cognitive intervention, despite the fact that WM was once
thought to be a fixed and highly heritable construct independent of environmental influences
(Miller 1956; Niaz and Logie 1993; Kremen et al. 2007; Engel et al. 2008). However, a
wealth of recent research measuring the pre- and postintervention changes in response to a
working memory training protocol support the plasticity of WM (Gunther et al. 2003; van’t
Hooft et al. 2003; Holmes et al. 2009; Klingberg 2009; Dahlin 2010; Holmes et al. 2010;
Klingberg 2010). Furthermore, changes have also been measured on a neuroimaging level
that show increased brain activity in parietal and frontal regions specific to WM after
training (Olesen et al. 2004; Westerberg and Klingberg 2007) and on a chemical level
through studies showing corresponding decreases in dopamine receptor D1 density as WM
performance increases in brain areas known to be critical to WM performance (McNab et al.
2009). It has been shown that dopamine is an important neurotransmitter during WM tasks,
a precise balance of which is necessary for optimal WM functioning such that too much or
too little would be detrimental (Luciana et al. 1992; Müller et al. 1998; McNab et al. 2009).
Much has been learned from studies of populations with Attention Deficit/ Hyperactivity
Disorder (ADHD) that can be applied to those with FXS with ADHD. WM is tied very
closely to attentional processes, and neuroimaging studies even indicate activation of similar
regions in the parietal and prefrontal lobes as controlled attention (Castellanos and Tannock
2002; Kane and Engle 2002; Olesen et al. 2004; Martinussen et al. 2005; Klingberg 2009;
Beck et al. 2010). Moreover, individuals with ADHD typically present with deficits in WM
function (Barkley 1996; Martinussen et al. 2005). Training in WM could therefore register
improvements in cognitive domains, such as attention and focus, and the use of Cogmed in
populations with ADHD has been well documented, with parents and teachers reporting
reductions of symptoms postintervention (Klingberg et al. 2002, 2005; Beck et al. 2010).
A large percentage, ranging from 41 to 93% based on previous studies, of children with FXS
also meet criteria from the Diagnostic and Statistical Manual for Mental Disorders (DSM
IV) for ADHD subtypes (Bregman et al. 1988; Freund et al. 1993; Mazzocco et al. 1998;
Backes et al. 2000). Furthermore, when compared to three other groups of intellectual
disability, the FXS group exhibits a distinct attention impairment above and beyond that
found in the other groups (Turk 1998; Munir et al. 2000; Cornish et al. 2004a), consistent
with assertions that the fundamental neurocognitive deficit in FXS is in controlling the flow
of input and (Cornish et al. 2004b; Mastergeorge et al. 2010), a function which is heavily
reliant on WM. In addition, it has been hypothesized that intracellular levels of FMRP may
rise in response to a WM load in typically developing individuals (Kwon et al. 2001), which
would explain the abundant WM difficulties seen in individuals with FXS (Kwon et al.
2001; Lanfranchi et al. 2009; Baker et al. 2011). This corroborates studies on the Wechsler
IQ scales which indicate that performance on the Digit Span subtest (a measure of WM)
correlates with FMRP levels in males with FXS (Mastergeorge et al. 2010). This WM deficit
is present even after controlling for overall IQ (Kwon et al. 2001), suggesting that there are
disproportionately large WM impairments in FXS even in relation to global cognitive
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impairment. All this is in line with previously described evidence of dopaminergic
dysfunction in FXS (Hjalgrim et al. 1999) and the critical role dopaminergic transmission
plays in WM function (Luciana et al. 1992; Müller et al. 1998; McNab et al. 2009;
Klingberg 2010). Taken together, the fragile X population, with so many core deficits
relating to WM and attentional dysfunction, is a prime candidate for Cogmed’s working
memory training.
Aside from the direct benefits that Cogmed can offer in the form of improvements in WM
and the related domains of attention and focus, recent studies on WM also implicate a
significant role in higher order cognitive functions such as learning, language/reading
comprehension, and reasoning ability (Kyllonen and Christal 1990; Daneman and Merikle
1996; Fry and Hale 2000; Kane et al. 2005; Dahlin 2010), all of which require holding and
consistently reevaluating information in WM in the midst of new incoming information.
Additionally, WM capacity has also been shown to be an effective longitudinal predictor of
academic achievement (Gathercole et al. 2003; Biederman et al. 2004; Alloway and
Alloway 2010), correlating most strongly with abilities in reading (Gathercole and Pickering
2000; Swanson and Sachse-Lee 2001b) and arithmetic (Swanson and Sachse-Lee 2001a;
Geary et al. 2004). Furthermore, other studies indicate a positive correlation between
performance on tasks measuring WM and tasks measuring fluid intelligence, or the ability to
reason out novel tasks independent of previously acquired knowledge (Gray et al. 2003;
Jaeggi et al. 2008). More broadly, WM tasks have also been shown to correlate with Charles
Spearman’s g (Suβ et al. 2002; Conway et al. 2003), a statistical variable describing the
theoretical general reasoning ability that underlies the shared variance between all cognitive
tests (Spearman 1927). In other words, people who perform well on one cognitive test
generally perform well on others, and the common denominator that promotes this
correlation is termed “g,” of which WM is thought to be the most important deriving factor
(Suβ et al. 2002). Therefore, training in working memory can have far-reaching effects
beyond merely the realm of ADHD; it can also positively influence general intellectual
functioning in many different domains of life. Since FXS is the most common known cause
of inherited intellectual disability (ID) (IQ < 70; Chonchaiya et al. 2009), WM cognitive
training is a natural intervention strategy to explore. Although to date no compelling
evidence exists of which the authors are aware that overall IQ scores are affected by WM
training, studies of this nature tend to involve IQ testing within a short time frame after
training (i.e., Holmes et al. 2010), which may not allow enough time for the full remediating
effects of WM training on learning and reasoning abilities to take effect. It’s possible that
given a longer time frame in the course of years after training, WM training may create a
positive feedback loop in which these individuals are more mentally engaged in all aspects
of their daily lives and are therefore more prone to further beneficial environmental
stimulation (thereby continuously maintaining their WM training), such that performance on
IQ tests may improve significantly. Additionally, it’s possible that although the effects of
WM training on IQ may not be readily apparent in populations such as ADHD, it may be
more so in a population such as FXS, where the initial deficits are more pronounced and the
lifetime intellectual trajectory has a downward trend relative to the general population,
thereby creating more room to detect improvement. This could be especially evident when
WM training is used in conjunction with partial correction of synaptic dysfunction by a
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targeted treatment regimen, such that new cognitive development, not possible with training
alone, can now be achieved.
In summary, the current and future aspects of intervention for FXS are promising for
improving not only the behavioral aspects but also the cognitive aspects of this syndrome.
Future FXS treatment may be a portal for understanding targeted treatments in a variety of
neurodevelopmental disorders including autism.
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